Evidence map›Paper›PMID 37514129›Full record

ArticlePharmaceutics2023

Synthesis, Characterization, and Therapeutic Efficacy of

Dragana Stanković, Magdalena Radović, Aljoša Stanković, Marija Mirković, Aleksandar Vukadinović, Milica Mijović, Zorana Milanović, Miloš Ognjanović, Drina Janković, Bratislav Antić and 3 more

Abstract read
In one paragraph

Article in Pharmaceutics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Review
  2. Article
  3. Molecules (Basel, Switzerland) · 2025
    Review
  4. Review
  5. Lignin-Based Nanocarrier for Simultaneous Delivery ofPharmaceuticals (Basel, Switzerland) · 2025
    Article
  6. Review
  7. Review
  8. Molecules (Basel, Switzerland) · 2024
    Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Dragana StankovićVinča Institute of Nuclear Sciences-National Institute of the Republic of Serbia, University of Belgrade, 11001 Belgrade, Serbia.ORCID 0000-0001-7669-2865
Magdalena RadovićVinča Institute of Nuclear Sciences-National Institute of the Republic of Serbia, University of Belgrade, 11001 Belgrade, Serbia.
Aljoša StankovićUniversity Clinical Centre of the Republic of Srpska, 78000 Banja Luka, Bosnia and Herzegovina.ORCID 0000-0002-1680-4260
Marija MirkovićVinča Institute of Nuclear Sciences-National Institute of the Republic of Serbia, University of Belgrade, 11001 Belgrade, Serbia.
Aleksandar VukadinovićVinča Institute of Nuclear Sciences-National Institute of the Republic of Serbia, University of Belgrade, 11001 Belgrade, Serbia.
Milica MijovićFaculty of Medicine, Institute of Pathology, University of Priština in Kosovska Mitrovica, 38220 Kosovska Mitrovica, Serbia.ORCID 0000-0003-1884-6066
Zorana MilanovićVinča Institute of Nuclear Sciences-National Institute of the Republic of Serbia, University of Belgrade, 11001 Belgrade, Serbia.ORCID 0000-0001-9953-3269
Miloš OgnjanovićVinča Institute of Nuclear Sciences-National Institute of the Republic of Serbia, University of Belgrade, 11001 Belgrade, Serbia.ORCID 0000-0003-2889-4416
Drina JankovićVinča Institute of Nuclear Sciences-National Institute of the Republic of Serbia, University of Belgrade, 11001 Belgrade, Serbia.
Bratislav AntićVinča Institute of Nuclear Sciences-National Institute of the Republic of Serbia, University of Belgrade, 11001 Belgrade, Serbia.
Sanja Vranješ-ĐurićVinča Institute of Nuclear Sciences-National Institute of the Republic of Serbia, University of Belgrade, 11001 Belgrade, Serbia.
Miroslav SavićFaculty of Pharmacy, University of Belgrade, 11000 Belgrade, Serbia.ORCID 0000-0002-6934-9193
Željko PrijovićVinča Institute of Nuclear Sciences-National Institute of the Republic of Serbia, University of Belgrade, 11001 Belgrade, Serbia.ORCID 0000-0003-1069-2453

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

As an alternative to classical brachytherapy, intratumoral injection of radionuclide-labeled nanoparticles (nanobrachytherapy, NBT) has been investigated as a superior delivery method over an intravenous route for radionuclide therapy of solid tumors. We created superparamagnetic iron oxide nanoparticles (SPIONs) coated with meso-1,2-dimercaptosuccinic acid (DMSA) and radiolabeled with Lutetium-177 (

Indexed as

177Lunanobrachytherapynanoparticlesradionuclide therapytumor

Identifiers

PMID37514129
PMCPMC10384743

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.